Syon Capital LLC Acquires Shares of 15,443 Alkermes plc (NASDAQ:ALKS)

Syon Capital LLC bought a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,443 shares of the company's stock, valued at approximately $444,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of Alkermes by 108.8% in the third quarter. Barclays PLC now owns 423,931 shares of the company's stock valued at $11,867,000 after acquiring an additional 220,893 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Alkermes during the 3rd quarter valued at $582,000. Tidal Investments LLC acquired a new position in shares of Alkermes during the 3rd quarter valued at $1,098,000. Franklin Resources Inc. raised its stake in shares of Alkermes by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 120,006 shares of the company's stock worth $3,486,000 after buying an additional 2,903 shares in the last quarter. Finally, Diversified Trust Co lifted its holdings in shares of Alkermes by 11.5% in the fourth quarter. Diversified Trust Co now owns 42,509 shares of the company's stock valued at $1,223,000 after buying an additional 4,378 shares during the period. Institutional investors own 95.21% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ALKS shares. UBS Group cut their price target on shares of Alkermes from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday. The Goldman Sachs Group upped their price target on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 14th. HC Wainwright reissued a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft boosted their target price on Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a research report on Thursday, March 27th. Finally, StockNews.com upgraded Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $38.08.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares in the company, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.40% of the stock is owned by corporate insiders.

Alkermes Price Performance

NASDAQ:ALKS traded up $0.07 during trading hours on Monday, reaching $27.91. The company's stock had a trading volume of 1,517,298 shares, compared to its average volume of 1,758,301. The company has a market cap of $4.60 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39. The business's 50-day moving average is $31.92 and its 200-day moving average is $30.43. Alkermes plc has a one year low of $22.90 and a one year high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. On average, sell-side analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.